본문 바로가기
  • Home

Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis)

  • CELLMED
  • Abbr : CellMed
  • 2021, 11(2), pp.9-9
  • DOI : 10.5667/CellMed.2021.0009
  • Publisher : Cellmed Orthocellular Medicine and Pharmaceutical Association
  • Research Area : Medicine and Pharmacy > General Medicine
  • Received : April 10, 2021
  • Accepted : May 13, 2021
  • Published : May 31, 2021

Mohd Abdul Kayum 1 Ifra Abdul Qaiyyum 1 Arzeena Jabeen 1 Mohammad Nawab 2

1National Research Institute of Unani Medicine for Skin Disorders
2Department of Moalajat, National Research Institute of Unani Medicine for Skin Disorders

Accredited

ABSTRACT

Nazla-i-muzmin (Chronic rhinosinusitis) is one of the commonest diseases prevalent all around the world. In India one in eight Indian suffers from this ailment. The current medical management and surgical intervention do not provide complete cure as a result there is a need to search a better alternative drug. The main objective of this study was to evaluate the safety and efficacy of a Unani formulation in the management of chronic rhinosinusitis. This study was designed as a randomised, controlled, parallel group and open label clinical study. It was carried out in 60 participants (30 participants in each group) of chronic rhinosinusitis aged between 18-65 years of either sex. The participants were enrolled based on the symptoms rhinorrhoea, sneezing, facial pain, nasal blockage, post nasal drip and thick nasal discharge. The participants of the test group was treated with a Unani formulation (9 gm) whereas Levocetrizine (10mg) was given to the participants of the control group once at night. In this study the average age of the participants was 30.36 (±10.20) years and 32.63 (±10.97) years in the control and test groups respectively with an average chronicity of 31.26 (± 43.46) months in the control group and 23.86 ± 39.4 months in the test group. The Unani formulation was found effective in reducing rhinorrhoea, sneezing, facial pain, nasal obstruction, post nasal discharge and thick nasal discharge. The snot score at post treatment comparing to the baseline was reduced to 2.1 and 2.0 in the test and control groups respectively. The Unani formulation improved the symptoms of chronic rhinosinusitis in the test group due to the possible action of the ingredients having, deobstruent, anti-inflammatory, concoctive, analgesic, expectorants and antimicrobial activities. It was concluded that the outcome of the study showed the successful management of chronic rhino-sinusitis. The formulation was well tolerated and showed no adverse effect.

Citation status

* References for papers published after 2022 are currently being built.